Optimizing Dosing Regimen of Piperacillin/Tazobactam for Nosocomial Pneumonia
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
1. To observe clinical and bacteriologic responses of different regimens of
piperacillin/tazobactam (4.5g q6h, prolonged or intermittent infusion) for treatment of
nosocomial pneumonia.
2. To describe the pharmacokinetic profile of piperacillin/tazobactam (4.5g q6h, prolonged
or intermittent infusion) in patients with nosocomial pneumonia.
3. To assess the safety profiles of piperacillin/tazobactam 4.5g q6h, prolonged or
intermittent infusion in patients with nosocomial pneumonia.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Collaborator:
Pfizer
Treatments:
Penicillanic Acid Piperacillin Piperacillin, tazobactam drug combination Tazobactam